基于网络药理学探讨四君子汤“异病同治”原发性肝癌与胃癌的作用机制
Exploring the Mechanism of Sijunzi Decoction of “Treating Different Diseases with the Same Method” in Treating Primary Liver Cancer and Gastric Cancer Based on Network Pharmacology
摘要: 目的:基于网络药理学研究四君子汤“异病同治”原发性肝癌与胃癌的通路及途径。方法:获得经方四君子汤活性成分,其通过TCMSP知识库,再利用Uniprot蛋白质元数据库转换所需的靶点基因。本文研究仅选用了四大数据库,其中数据库为TTD、GeneCards、DrugBank及OMIM,处理此四个数据库数据相互增补原发性肝癌(Primary liver cancer, PLC)和胃癌(Gastric cancer, GC)疾病关键靶向基因,再引用JVENN网站绘制韦恩图,得到处理后韦恩图具体数据,再通过Cytoscape 3.9.1软件工具构建“药物–活性成分–靶点–疾病”关系网络图。再进一步利用STRING数据库,输入数据中得到的关键靶向点,绘制蛋白质相互关系图(PPI),再次使用Cytoscape 3.9.1软件中的扩展程序中的相关指标值(度值,degree;介数,Betweenness),将PPI的核心靶点与靶向预测进行分析。最后就是进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路富集分析,同样在DAVID数据库帮助下对上述处理后得到的数据分析。结果:本文研究中的经方经过数据重重筛选,治疗异病PLC与GC的有效成分和目标靶向点分别是114个和106个,而较相关的关键靶点经degree值排名前八有丝氨酸/苏氨酸蛋白激酶(AKT1)、肿瘤抑制基因P53 (TP53)、血管内皮生长因子A (VEGFA)、胱天蛋白酶3 (CASP3)、肿瘤坏死因子(TNF)、核蛋白类癌基因(MYC)、前列腺素内过氧化物合酶2 (PTGS2)、白细胞介素-1β (IL1B)。在基因本体中生物功能的富集分析重点显示了基因表达正向调控方面上显著为高通路,同时也反映在药物反应及转录DNA模板正向调控的重要性信号通路。结论:本文基于中医理论与网络药理学的研究表明,经方四君子汤异病同治PLC、GC是多通路、多途径、多靶点的极为复杂过程,主要通过参与细胞的基因正向表达、转录DNA表达、药物反应、多种相关酶的调控等发挥治疗疾病的作用。
Abstract: Objective: To study the Mechanism of Action of Sijunzi Decoction on “Same Treatment for Different Diseases” in Primary Liver Cancer and Gastric Cancer Based on Network Pharmacology. Method: We get the active ingredients of Sijunzi Decoction, use the TCMSP knowledge base and then use the Uniprot Protein Element database to convert the necessary target genes. This study selected only four major databases, including TTD, GeneCards, DrugBank and OMIM, which were processed to supplement the major target genomes of primary liver cancer (PLC) and stomach cancer (GC), and then used the JVENN website to draw Wayne maps. After processing specific data from the Wayne map, the software tool Cytoscape 3.9.1 was used to create a network diagram of “drug-active-target- disease. Next, we use the STRING database to enter the most important target points obtained from the data, create a Protein Interaction Chart (PPI) and analyze the most important PPI target points with target predictions again with the corresponding indicator values (degree, precipitation, median, Bedouin) in the Cytoscape 3.9.1 software extension. Finally, it includes gene concentration analysis (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), as well as data obtained through analysis and processing by the David database. Result: In this study, the menstrual diet was carefully validated against data. The active ingredients and targets for the treatment of heterogeneous PLC and GC were 114 and 106 respectively. The more relevant key targets were evaluated using the first eight degrees of serine/sulfate kinase (AKT1), namely the tumor suppressor gene P53 (TP53), Endothelial growth factor A (VEGFA), vesicular protease 3 (CASP3), tumour necrosis factor TNF, nucleic acid oncogen (MYC) and interleukin-1β (IL1B). Analysis of the concentration of biological functions in the genome shows that gene expression in positive regulation is significantly higher, which is also reflected in important signaling pathways that positively regulate drug response and DNA transcription patterns. Conclusion: Based on the theory of traditional Chinese medicine and research of network pharmacology, this article points out that PLC and GC are extremely complex processes with multiple pathways, channels and applications that are mainly involved in positive expression of cellular genes, transcription of DNA expression, and drug reactions. It regulates and controls various related enzymes to exert therapeutic effects on disease.
文章引用:李锦湘. 基于网络药理学探讨四君子汤“异病同治”原发性肝癌与胃癌的作用机制[J]. 中医学, 2023, 12(6): 1496-1510. https://doi.org/10.12677/TCM.2023.126223

参考文献

[1] Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E. and Heikenwalder, M. (2018) The Immunology of Hepatocellular Carcinoma. Nature Immunology, 19, 222-232. [Google Scholar] [CrossRef] [PubMed]
[2] Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L. and Heikenwalder, M. (2021) The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer. Nature Reviews Cancer, 21, 541-557. [Google Scholar] [CrossRef] [PubMed]
[3] Kanwal, F., Kramer, J.R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P.A., Li, L., Desiderio, R., Thrift, A.P., Asch, S.M., Chu, J. and El-Serag, H.B. (2018) Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology, 155, 1828-1837. [Google Scholar] [CrossRef] [PubMed]
[4] Venerito, M., Link, A., Rokkas, T. and Malfertheiner, P. (2016) Gastric Cancer—Clinical and Epidemiological Aspects. Helicobacter, 21, 39-44. [Google Scholar] [CrossRef] [PubMed]
[5] 潘才豪. 原发性肝癌的中医治疗[C]//李俊德. 2013年中医、中西医结合防治肝癌、肝病高峰论坛论文集: 2013年卷, 2013: 121-131.
[6] 丁园园. 胃癌中医证型、证候及相关性研究[D]: [硕士学位论文]. 沈阳: 辽宁中医药大学, 2011.
[7] 张艳梅. 四君子汤治疗中医内科疾病脾胃气虚证的疗效[J]. 中医临床研究, 2022, 14(9): 100-102.
[8] 李紫瑞, 王坚, 王瑞平. 中医疏肝健脾法治疗肝癌的研究进展[J]. 现代中西医结合杂志, 2021, 30(21): 2383-2388.
[9] 郑蔚婵, 李辉, 龚雯婧. 复方皂角刺膏外敷治疗原发性肝癌重度癌性疼痛28例临床观察[J]. 湖南中医杂志, 2022, 38(10): 8-11.
[10] Kong, D., Chen, H., Chen, W., Liu, S., Wang, H., Wu, T., Lu, H., Kong, Q., Huang, X. and Lu, Z. (2013) Gene Expression Profiling Analysis of Hepatocellular Carcinoma. European Journal of Medical Research, 18, Article No. 44. [Google Scholar] [CrossRef
[11] Ghatak, S., Lalnunhlimi, S., Lalrohlui, F., Pautu, J.L., Zohmingthanga, J., Kunnumakkara, A.B. and Kumar, N.S. (2018) Novel AKT1 Mutations Associated with Cell-Cycle Abnormalities in Gastric Carcinoma. Personalized Medicine, 15, 79-86. [Google Scholar] [CrossRef] [PubMed]
[12] Deng, W., Hao, Q., Vadgama, J. and Wu, Y. (2021) Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer. Journal of Cancer Science and Clinical Therapeutics, 5, 134-153. [Google Scholar] [CrossRef] [PubMed]
[13] Castanhole-Nunes, M.M.U., Tunissiolli, N.M., Oliveira, A.R.C.P., Mattos, M.F., Galbiatti-Dias, A.L.S., Kawasaki- Oyama, R.S., Pavarino, E.C., Da Silva, R.F. and Goloni-Bertollo, E.M. (2022) MiR-612, miR-637, and miR-874 Can Regulate VEGFA Expression in Hepatocellular Carcinoma Cell Lines. Genes, 13, Article No. 282. [Google Scholar] [CrossRef] [PubMed]
[14] Zhou, M., Liu, X., Li, Z., Huang, Q., Li, F. and Li, C.-Y. (2018) Caspase-3 Regulates the Migration, Invasion and Metastasis of Colon Cancer Cells. International Journal of Cancer, 143, 921-930. [Google Scholar] [CrossRef] [PubMed]
[15] Ma, X.Y., Zhang, M., Fang, G., Cheng, C.J., Wang, M.K., Han, Y.M., Hou, X.T., Hao, E.W., Hou, Y.Y. and Bai, G. (2021) Ursolic Acid Reduces Hepatocellular Apoptosis and Alleviates Alcohol-Induced Liver Injury via Irreversible Inhibition of CASP3 in Vivo. Acta Pharmacologica Sinica, 42, 1101-1110. [Google Scholar] [CrossRef] [PubMed]
[16] Wahlström, T. and Henriksson, M.A. (2015) Impact of MYC in Regulation of Tumor Cell Metabolism. Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mechanisms, 1849, 563-569. [Google Scholar] [CrossRef] [PubMed]
[17] Ulrich, C.M., Whitton, J., Yu, J.-H., et al. (2005) PTGS2 (COX-2) −765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs. Cancer Epidemiology, Biomarkers & Prevention, 14, 616-619. [Google Scholar] [CrossRef
[18] Lewis, A.M., Varghese, S., Xu, H. and Alexander, H.R. (2006) Interleukin-1 and Cancer Progression: The Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment. Journal of Translational Medicine, 4, Article No. 48. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, C.-Y., Chen, J., He, L. and Stiles, B.L. (2018) PTEN: Tumor Suppressor and Metabolic Regulator. Frontiers in Endocrinology, 9, Article 338. [Google Scholar] [CrossRef] [PubMed]
[20] Davis, R.K. and Chellappan, S. (2008) Disrupting the Rb-Raf-1 Interaction: A Potential Therapeutic Target for Cancer. Drug News & Perspectives, 21, 331-335. [Google Scholar] [CrossRef] [PubMed]
[21] Duda, P., Akula, S.M., Abrams, S.L., Steelman, L.S., Martelli, A.M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., Cervello, M., Gizak, A., Rakus, D. and McCubrey, J.A. (2020) Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 9, Article No. 1110. [Google Scholar] [CrossRef] [PubMed]
[22] Papadopoli, D., Pollak, M. and Topisirovic, I. (2021) The Role of GSK3 in Metabolic Pathway Perturbations in Cancer. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1868, Article ID: 119059. [Google Scholar] [CrossRef] [PubMed]
[23] Ebrahim, A.S., Sabbagh, H., Liddane, A., Raufi, A., Kandouz, M. and Al-Katib, A. (2016) Hematologic Malignancies: Newer Strategies to Counter the BCL-2 Protein. Journal of Cancer Research and Clinical Oncology, 142, 2013-2022. [Google Scholar] [CrossRef] [PubMed]
[24] Gaptulbarova, K.A., Tsyganov, M.M., Pevzner, A.M., Ibragimova, M.K. and Litviakov, N.V. (2020) NF-κB as a Potential Prognostic Marker and a Candidate for Targeted Therapy of Cancer. Experimental Oncology, 42, 263-269.
[25] Stein, Y., Rotter, V. and Aloni-Grinstein, R. (2019) Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. International Journal of Molecular Sciences, 20, Article No. 6197. [Google Scholar] [CrossRef] [PubMed]
[26] Duffy, M.J., O’Grady, S., Tang, M. and Crown, J. (2021) MYC as a Target for Cancer Treatment. Cancer Treatment Reviews, 94, Article ID: 102154. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, H., Liu, H. and Qing, G. (2018) Targeting Oncogenic Myc as a Strategy for Cancer Treatment. Signal Transduction and Targeted Therapy, 3, Article No. 5. [Google Scholar] [CrossRef] [PubMed]